Featured Articles and Interviews
Jul 24, 2025
Biotech and Pharma Market Update: Q2 2025 in Review
More Featured Articles and Inverviews
Press Releases
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its lead CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.